{
  "trial_id": "NCT01295944",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histologically proven intra-cranial or spinal ependymoma or anaplastic ependymoma.",
      "label": "met",
      "evidence": "The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation."
    },
    {
      "criterion": "Pathologic or imaging confirmation of tumor progression or regrowth.",
      "label": "met",
      "evidence": "MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma."
    },
    {
      "criterion": "At least 1 block of tissue or 15 unstained slides at a minimum available for central pathology review.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must be greater than or equal to 18 years old.",
      "label": "met",
      "evidence": "Patient is a 45-year-old man."
    },
    {
      "criterion": "Patients must have a Karnofsky performance status of > 60.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have adequate bone marrow function (WBC greater than or equal to 3,000/microliter, ANC greater than or equal to 1,500/mm^3, platelet count of greater than or equal to 100,000/mm^3, and hemoglobin greater than or equal to 10 gm/dl).",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have shown unequivocal radiographic evidence for tumor progression by MRI or CT scan.",
      "label": "met",
      "evidence": "MRI showed a spinal cord conus mass which was biopsied and found to be anaplastic astrocytoma."
    },
    {
      "criterion": "Patients must have recovered from the toxic effects of prior therapy: greater than or equal to 28 days from any investigational agent, greater than or equal to 28 days from prior cytotoxic therapy.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply: They have recovered from the effects of surgery. A minimum of 28 days have elapsed from the day of surgery to the day of registration.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients must have failed prior radiation therapy* and must have an interval of greater than or equal to 42 days from the completion of radiation therapy to study entry.",
      "label": "met",
      "evidence": "The tumor is located in the T-L spine, unresectable anaplastic astrocytoma s/p radiation."
    },
    {
      "criterion": "Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either PET or Thallium scanning, MR spectroscopy, or surgical/pathological documentation of disease.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Women of childbearing potential must have a negative B-HCG pregnancy test documented within 14 days prior to registration.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with any significant medical illnesses that in the investigator s opinion cannot be adequately controlled with appropriate therapy or would compromise the patient s ability to tolerate this therapy.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg) despite antihypertensive medication.",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "New York Heart Association (NYHA) Grade II or greater congestive heart failure.",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Unknown Karnofsky performance status, adequate bone marrow function, and recovery from prior therapy. Also unknown is the patient's ability to tolerate this therapy due to significant medical illnesses.",
  "_meta": {
    "topic_id": "1",
    "trial_id": "NCT01295944",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b"
  }
}